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Background: Data on the genetic variants for type 2 diabetes mellitus (T2DM) in sub-Saharan African populations
are very scarce. This study aimed to investigate the association of transcription factor 7-like (TCF7L2) with T2DM in a
Cameroonian population and explore possible genotype-phenotype correlation.
Methods: This is a case–control study involving 37 T2DM patients and 37 non-diabetic volunteers of Cameroonian
ethnicity aged 40 years old and above. We collected clinical and biological data to determine phenotypic traits.
TCF7L2 was analyzed by genotyping for rs7903146 (C/T) using PCR-RFLP. Biochemical analyses were performed
using a spectrophotometer with Chronolab kits. Statistical analyses were carried out using IBM SPSS, PS and
Quanto.
Results: TCF7L2 was associated with T2DM in this Cameroonian population (p = 0.013 for alleles, and p = 0.013 for
genotypes). The risk allele was C (9.5% patients vs. 0% healthy controls, OR = 16.56) and the protective allele was
T (90.5% patients vs. 100.0% healthy controls, OR = 0.06). The risk genotype was C/T (18.9% patients vs. 0% healthy
controls, OR = 18.44), while the protective genotype was T/T (81.1% patients vs. 100.0% healthy controls, OR = 0.054).
The statistical power was 99.99%. TCF7L2 was not preferentially associated with a specific disease phenotype.
Conclusion: TCF7L2 is associated with T2DM in this Cameroonian population. The association is not dependent on a
specific T2DM phenotype. Clinical genetic testing for TCF7L2 can help to predict the occurrence of T2DM in Cameroon.
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Type 2 diabetes mellitus (T2DM) is a metabolic disease
characterized by hyperglycemia that can occur as a
result of impaired insulin secretion, insulin resistance in
peripheral tissues and increased hepatic glucose output
[1]. T2DM causes significant morbidity, disability and
early mortality, and imposes a huge economic burden
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article, unless otherwise stated.[2,3]. T2DM has reached epidemic proportions world-
wide. The International Diabetes Federation (IDF) esti-
mates the number of adults with diabetes in the world at
381.8 million in 2013, a number that will expand to
591.9 million in 2035. The increase of the prevalence of
diabetes will be highest in sub-Saharan Africa, with a
projected growth of 109.6%, from 19.8 million in 2013 to
41.5 million in 2035 [3].
T2DM involves a complex interaction between genetic
and environmental factors such as dietary habits and
lifestyle. It is often associated with a strong genetic pre-
disposition but the genetics of this form of diabetes re-
mains complex and not well understood [4]. With the
advent of high throughput genome-wide associationCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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identified [5], including the transcription factor 7-like 2
(TCF7L2) which is involved in insulin secretion [6,7].
Following the initial publication of an association of
common variants in TCF7L2 with T2DM in people of
European descent [8], an avalanche of replication reports
has confirmed this finding and demonstrated that this
genetic association is highly reproducible in various ethnic
populations [9-20]. A large Human Genome Epidemiology
(HuGE) review and meta-analysis has suggested that
TCF7L2 is involved in near 1/5 of all T2DM [21].
Africans harbour an increased susceptibility in the inci-
dence of T2DM and the occurrence of complications [22].
However, the genetic basis of T2DM in native African
populations has been understudied. The determination of
genetic risk factors of T2DM in sub-Saharan African pop-
ulations that will face the largest increase of the preva-
lence of diabetes in the next decades is highly desirable.
Such data might improve the prediction, prevention,
stratification, disease management and enhance the un-
derstanding of the heterogeneity and pathophysiology of
T2DM in sub-Saharan African populations.
The association of TCF7L2 with T2DM has not been
studied in Cameroon till date. The aim of this study was
to evaluate the association of the TCF7L2 rs7903146
(C/T) gene polymorphism with T2DM in a Cameroonian




Ethical clearance was obtained from the National Ethical
Review Board of the Cameroon Ministry of Public
Health. Written informed consent was obtained from all
the participants. The study was conducted in accordance
with the Helsinki Declaration.
Study population
This is a case–control study involving 37 T2DM patients
and 37 non-diabetic volunteers of Cameroonian ethnicity
aged 40 years old and above. T2DM patients, diagnosed
according to the IDF criteria [23], were consecutively re-
cruited through the outpatient clinic of the National
Obesity Center of the Yaoundé Central Hospital. Non-
diabetic controls were recruited from the general popula-
tion and included in the study after being tested negative
for diabetes.
For all participants, we collected data on the sex and
age; we measured height, waist and hip circumference to
the nearest 0.5 cm, and weight in light clothes to the
nearest 0.1 kg, and we then calculated the body mass
index (BMI) as weight in kg/height2 in m2, and the
waist-to-hip ratio. Blood pressure was reported as the
mean of two measurements performed at least threeminutes apart, in the right arm with the subject sited
after a 15-min rest with an automatic sphygmomanom-
eter Omron HEM-705 CP (Omron Corporation, Tokyo,
Japan). We collected blood samples for biochemical and
molecular assays.
Biochemical assays
Fasting plasma glucose (glucose oxidase–peroxidase
method), serum cholesterol (cholesterol oxidase phenol4-
amino antipyrene peroxidase method), serum triglycerides
(glycerol phosphatase oxidase − phenol4-amino antipyrene
peroxidase method), and high-density lipoprotein (HDL)-
cholesterol (cholesterol oxidase phenol4-amino antipyrene
peroxidase method) were measured on a spectropho-
tometer (UV Mini 1240) using Chronolab kits (Chron-
olab Systems, Barcelona, Spain). Low-density lipoprotein
(LDL)-cholesterol was calculated using the Friedwald’s
formula [24].
DNA extraction and molecular genotyping
DNA was extracted from whole blood on filter paper by
the Chelex method. Seventy-four participants (37 type 2
diabetic patients and 37 controls) were genotyped for
TCF7L2 rs7903146 by Polymerase Chain Reaction-
Restriction Fragment Length Polymorphism (PCR-
RFLP). The TCF7L2 rs7903146 (C/T) polymorphism
was genotyped using the following primers: Forward
5’-AAG AGA AGA TTC CTT TTT AAA TGG TG-3’,
Reverse 5’-CCT CAT ACG GCA ATT AAA TTA TAC
A-3’ (SIGMA-ALDRICH, St. Louis, Missouri, United
States). A final reaction volume of 15 μL for the Poly-
merase Chain Reaction (PCR) was constituted, which
contained 100 ng of genomic DNA, 5 pmol of each pri-
mer, PCR buffer with 1 mmol/L of MgCl2, 100 μmol/L
of each deoxynucleotide triphosphate (dNTP), 0.5 U of
Hot Start Taq DNA polymerase (QIAGEN) and 7.8 μl
of nuclease free water. The PCR was carried out on a
BIOMETRA T3 Thermal Cycler under the following
conditions: 95°C for 15 minutes, followed by 34 cycles
of 95°C for 30 seconds, 58°C for 30 seconds, 72°C for
30 seconds, and a final extension of 72°C for 9 minutes.
The amplicons were analyzed by agarose gel electrophor-
esis using a 3% agarose gel and positive amplicons
digested with Helicobacter pylori CH4 III (Hpy-CH4III)
restriction enzyme at 37°C overnight. The resulting prod-
ucts were separated by electrophoresis on a 2% agarose
gel and visualized under a UV transilluminator.
Sample size calculation
The sample size required to detect the disease variant
with an OR of 10 and an expected allele frequency of
0.10 in the general population, with α = 0.05 and β = 0.20
was 21 T2DM patients and 21 healthy controls. The
prospective and post-hoc statistical power analyses were
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software and the Quanto statistical program [25].
Statistical analysis
Allele and genotype frequencies in patients and controls
were estimated by direct counting. Qualitative variables
were analyzed by chi square (χ2) test with Yates’ continu-
ity correction or the Fisher’s exact test when appropriate
using Epi Info version 6 (USD, Stone Mountain, USA).
Quantitative variables were analyzed by Mann–Whitney
U-test statistics using the Statistical Package for Social
Science (SPSS) version 20.0 for Windows (SPSS, Chicago,
Illinois, USA). A p value less than 0.05 was considered sta-
tistically significant.
Results
Characteristics of the study population
As depicted in Table 1, significant differences between
T2DM patients and healthy controls were observed for
age (median age - 60.00 yrs vs 50.00, p < 0.0001), waist-to-
hip ratio (median value - 0.97 vs 1.0, p < 0.0001), fasting
plasma glucose (median level - 1.57 vs 1.00, p < 0.0001),
total cholesterol (median level - 157.00 vs 197.00, p <
0.0001), HDL-cholesterol (median level - 46.00 vs 50.00,
p < 0.005) and LDL-cholesterol (median level - 82.00 vs
113.00, p < 0.0001).
Genetic variants and type diabetes mellitus
The study population was in Hardy-Weinberg equilibrium
(χ2 = 0.18, p = 0.67). TCF7L2 rs7903146 (C/T) was asso-
ciated with T2DM (p = 0.013 for alleles, and p = 0.013Table 1 Characteristics of the study population
Characteristics Type 2 diabetes patients
n = 37
Demographic
Male/female (ratio) 17/20 (0.85)
Age (years) 60.00 (55.00 – 65.00)
Clinical
WHR 0.97 (0.92 – 0.99)
SBP (mmHg) 128.00 (115.00 – 150.00)
DBP (mmHg) 76.00 (71.50 – 86.50)
BMI (kg/m2) 28.07 (25.14 – 35.84)
Biological
FPG (g/L) 1.57 (1.30 – 2.30)
TC (mg/dl) 157.00 (143.00 – 174.00)
HDL-C (mg/dl) 46.00 (39.00 – 51.00)
LDL-C (mg/dl) 82.00 (74.00 – 96.50)
TG (mg/dl) 139.00 (121.00 – 158.00)
Data are medians (interquartile range) unless otherwise stated.
WHR: waist-to-hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure;
HDL: high density lipoprotein cholesterol; LDL: low density lipoprotein cholesterol: Tfor genotypes), Table 2. The minor allele was C and the
major allele was T. The C allele was determined to be
the risk allele (9.5% patients vs. 0% healthy controls,
OR = 16.56), while the T allele was determined to be the
protective allele (90.5% patients vs. 100.0% healthy con-
trols, OR = 0.06). The C/C genotype was completely ab-
sent in the study population. The C/T genotype was the
risk genotype (18.9% patients vs. 0% healthy controls,
OR = 18.44), while the T/T genotype was the protective
genotype (81.1% patients vs. 100.0% healthy controls,
OR = 0.054).
Genotype-phenotype correlation
We performed genotype-phenotype correlations to deter-
mine if the inaugural disease phenotype varies according to
TCF7L2 genotypes. Since the homozygous C/C genotype
was absent in our study population, the protective T/T
genotype was modeled relative to the susceptible C/T geno-
type in all case-only analyses. This case-only analyses were
performed according to phenotypic characteristics such
as sex, age at diabetes onset, BMI, waist-to-hip ratio,
systolic blood pressure and diastolic blood pressure,
fasting plasma glucose, total cholesterol, LDL-cholesterol,
HDL-cholesterol and triglycerides. No significant genotype-
phenotype correlation was observed in the current study,
meaning that TCF7L2 genotypes were not preferentially as-
sociated with a specific T2DM phenotype (data not shown).
Discussion
Despite the growing burden of non-communicable dis-
eases in Africa, especially diabetes, Africans have onlyHealthy controls p value
n = 37
15/22 (0.68) 0.407
50.00 (45.00 – 54.50) < 0.0001
1.0 (1.0 – 1.0) < 0.0001
135.00 (120.50 – 155.50) 0.384
84.00 (73.50 – 97.50) 0.068
28.00 (26.00 – 32.50) 0.905
1.00 (1.00 – 1.00) < 0.0001
197.00 (173.00 – 219.50) < 0.0001
50.00 (45.50 – 56.00) 0.005
113.00 (94.00 – 144.00) < 0.0001
143.00 (130.50 – 167.50) 0.191
BMI: body mass index; FPG: fasting plasma glucose; TC: total cholesterol;
G: triglycerides.
Table 2 Case–control association analysis of TCF7L2 rs7903146 (C/T) with type 2 diabetes
TCF7L2 rs7903146 (C/T) Type 2 diabetic patients Healthy controls OR (95% CI) p value
Alleles
C 7 (9.5%) 0 (0%) 16.56 (0.92 – 295.41) 0.013
T 67 (90.5%) 74 (100.0%) 1
Total (2n) 74 (100.0%) 74 (100.0%)
Genotypes
C/T 7 (18.9%) 0 (0%) 18.44 (1.01 – 335.97) 0.011
T/T 30 (81.1%) 37 (100.0%) 1
Total (n) 37 (100.0%) 37 (100.0%)
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there is dearth information on the genetic variants for
T2DM in sub-Saharan African populations. Our study
provides first-time insight into the role of the TCF7L2
rs7903146 (C/T) gene polymorphism in T2DM among
Cameroonians. Our findings demonstrate that TCF7L2 is
a susceptibility locus for T2DM and rs7903146 (C/T) a
marker for the effect in the Cameroonian population.
This finding is consistent with those of other studies in
diverse ethnic populations [9-20].
Studies have shown that frequencies of the T allele are
highest in Africa, moderate in Asia, and lowest in
North-America and Europe [27]. Indeed, as found in a
West-African population [18], the T allele was very
frequent in our population. Contrary to other studies
the T allele was not associated with T2DM, but yielded a
protective effect in our population. Less than 10% of in-
dividuals carried the risk allele C, while those carrying
the homozygous combination were rare. The back-
ground frequencies of the TCF7L2 alleles and genotypes
were different between this Cameroonian population
and populations of European, Asian and American an-
cestries [27], indicating genetic heterogeneity across
populations and ancestries on this locus. Although the
background frequencies varies widely according to ethni-
city, TCF7L2 essentially conveyed similar risk in different
populations.
TCF7L2 was not preferentially associated with a specific
disease phenotype. The association of TCF7L2 with
T2DM independently of BMI and waist-to-hip ratio sup-
ports the concept of impaired insulin secretion via a defi-
ciency of the TCF proteins which are the gene products of
TCF7L2 [21]. This is consistent with the potential role of
the human TCF7L2 protein in the development of several
cell lineages and organs including pancreatic islet develop-
ment and in adipogenesis, beta-cell survival and insulin
secretory granule function, myogenesis and transcriptional
regulation of genes for pro-glucagon and glucagon-like
peptides (GLP-1 and GLP-2) [22].
Even though the pathophysiology of T2DM remains
unclear, there is substantial evidence to suggest that theTCF7L2 gene strongly predicts the development of
TD2M in several ethnic populations and can be consid-
ered an important screening tool to identify the popula-
tion at risk. Therefore, clinical genetic testing for
TCF7L2 should be considered as an actionable indicator
for early intervention and prevention of T2DM in
Cameroon and sub-Saharan Africa. Also, the confirm-
ation of the association of TCF7L2 with T2DM in an
independent population provides evidence for further
consideration of TCF7L2 and related molecules and
pathways as potential therapeutic targets for T2DM.
Conclusion
TCF7L2 gene is strongly associated with T2DM in this
Cameroonian population. The association is not dependent
on a specific T2DM phenotype. Clinical genetic testing for
TCF7L2 can help to predict the occurrence of T2DM in
the sub-Saharan African populations.
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